Outcomes After Autologous SCT in Lymphoma Patients Grouped by Weight

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2015 Feb 10

PMID 25665041

Citations 3

Authors

J E Lau

C Weber

M Earl

L A Rybicki

K D Carlstrom

C M Wenzell

B T Hill

N S Majhail

M Kalaycio

Affiliations

Soon will be listed here.

Abstract

Obesity continues to be an increasing global health issue contributing to the complexity of chemotherapy dosing in the field of SCT. Investigation into the optimal dosing weight used to calculate chemotherapy doses in obese patients undergoing SCT is limited and inconclusive. Our single-center, retrospective study compared safety and efficacy outcomes by body mass index (BMI) for 476 adult lymphoma patients who underwent auto-SCT with a myeloablative chemotherapeutic regimen of BU, CY and etoposide dosed using adjusted body weight. Three weight groups categorized based on BMI were defined: normal/underweight ⩽24.9 kg/m(2), overweight 25-29.9 kg/m(2) and obese ⩾30 kg/m(2). Severity of mucositis, incidence of secondary malignancy, incidence of bacteremia and median hospital length of stay did not differ among the groups. The median times to absolute neutrophil count and platelet recovery were 10 days (P=0.75) and 14 days (P=0.17), respectively. Obese patients had a lower 100-day mortality compared with other weight groups, although this did not translate into an OS benefit. OS and disease relapse were similar among the groups. Our study demonstrates that use of adjusted body weight to calculate chemotherapy doses does not negatively have an impact on outcomes in obese patients undergoing auto-SCT with BU, CY and etoposide.

Citing Articles

Post-Transplant Cyclophosphamide for the Prevention of Graft-vs.-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Guide to Management for the Advanced Practitioner.

Kachur E, Patel J, Morse A, Moore D, Arnall J J Adv Pract Oncol. 2023; 14(6):520-532.

PMID: 37808076 PMC: 10558021. DOI: 10.6004/jadpro.2023.14.6.5.

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation.

Bachanova V, Rogosheske J, Shanley R, Burns L, Smith S, Weisdorf D Biol Blood Marrow Transplant. 2015; 22(3):571-4.

PMID: 26497907 PMC: 4753782. DOI: 10.1016/j.bbmt.2015.10.012.

A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients.

Berger N Bone Marrow Transplant. 2015; 50(5):617-8.

PMID: 25730189 DOI: 10.1038/bmt.2015.26.

References

Navarro W, Agovi M, Logan B, Ballen K, Bolwell B, Frangoul H . Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant. 2010; 16(10):1442-50. PMC: 2933950. DOI: 10.1016/j.bbmt.2010.04.009. View

Andersson B, Thall P, Madden T, Couriel D, Wang X, Tran H . Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002; 8(9):477-85. DOI: 10.1053/bbmt.2002.v8.pm12374452. View

Hadjibabaie M, Iravani M, Taghizadeh M, Ataie-Jafari A, Shamshiri A, Mousavi S . Evaluation of nutritional status in patients undergoing hematopoietic SCT. Bone Marrow Transplant. 2008; 42(7):469-73. DOI: 10.1038/bmt.2008.188. View

Lopes-Serrao M, Gressett Ussery S, Hall 2nd R, Shah S . Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing. J Oncol Pract. 2011; 7(1):13-7. PMC: 3014502. DOI: 10.1200/JOP.2010.000045. View

Deeg H, Seidel K, Bruemmer B, Pepe M, Appelbaum F . Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant. 1995; 15(3):461-8. View

Radich J, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M . HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003; 102(1):31-5. DOI: 10.1182/blood-2002-08-2619. View

Kaestner S, Sewell G . Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol). 2007; 19(1):23-37. DOI: 10.1016/j.clon.2006.10.010. View

Slattery J, Clift R, Buckner C, Radich J, Storer B, Bensinger W . Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89(8):3055-60. View

. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2001; 894:i-xii, 1-253. View

10.

Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F . Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002; 81(2):96-102. DOI: 10.1007/s00277-001-0413-8. View

11.

Bubalo J, Carpenter P, Majhail N, Perales M, Marks D, Shaughnessy P . Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014; 20(5):600-16. DOI: 10.1016/j.bbmt.2014.01.019. View

12.

Horan T, Andrus M, Dudeck M . CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36(5):309-32. DOI: 10.1016/j.ajic.2008.03.002. View

13.

Field K, Kosmider S, Jefford M, Michael M, Jennens R, Green M . Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract. 2010; 4(3):108-13. PMC: 2794002. DOI: 10.1200/JOP.0832001. View

14.

Tarella C, Caracciolo D, Gavarotti P, Argentino C, Zallio F, Corradini P . Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant. 2001; 26(11):1185-91. DOI: 10.1038/sj.bmt.1702692. View

15.

Nguyen L, Leger F, Lennon S, Puozzo C . Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2005; 57(2):191-8. DOI: 10.1007/s00280-005-0029-0. View

16.

Griggs J, Mangu P, Anderson H, Balaban E, Dignam J, Hryniuk W . Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012; 30(13):1553-61. DOI: 10.1200/JCO.2011.39.9436. View

17.

Hunter R, Navo M, Thaker P, Bodurka D, Wolf J, Smith J . Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2008; 35(1):69-78. DOI: 10.1016/j.ctrv.2008.07.005. View

18.

Kim J, Lee D, Yoo C, Kim S, Kim S, Lee J . BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2010; 35(2):183-7. DOI: 10.1016/j.leukres.2010.07.016. View

19.

Copelan E, Penza S, Pohlman B, Avalos B, Goormastic M, Andresen S . Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000; 25(12):1243-8. DOI: 10.1038/sj.bmt.1702433. View

20.

Zhang H, Graiser M, Hutcherson D, Dada M, McMillan S, Ali Z . Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2012; 18(8):1287-94. DOI: 10.1016/j.bbmt.2012.02.006. View